Promising approach
MyJourneywithCancer
Member Posts: 82
As I am waiting to read the full text, I would like to share this:
Next Generation Sequencing (NGS) is becoming a reliable approach for molecular profiling and treatment decision for non-small cell lung cancer (NSCLC) patients. At least one genetic alteration was found in 78% of the patients. 23% patients showed mutations for which approved (ALK, EGFR, ROS1) or emerging (BRAF, ERBB2, MET, RET) targeted therapies exist.
The details are here: https://www.ncbi.nlm.nih.gov/pubmed/29130105
Next Generation Sequencing (NGS) is becoming a reliable approach for molecular profiling and treatment decision for non-small cell lung cancer (NSCLC) patients. At least one genetic alteration was found in 78% of the patients. 23% patients showed mutations for which approved (ALK, EGFR, ROS1) or emerging (BRAF, ERBB2, MET, RET) targeted therapies exist.
The details are here: https://www.ncbi.nlm.nih.gov/pubmed/29130105
0
Discussion Boards
- 119.2K All Discussion Boards
- 5 CSN Information
- 5 Welcome to CSN
- 119.3K Cancer specific
- 2.7K Anal Cancer
- 424 Bladder Cancer
- 297 Bone Cancers
- 1.6K Brain Cancer
- 28.1K Breast Cancer
- 376 Childhood Cancers
- 27.7K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.6K Head and Neck Cancer
- 6.2K Kidney Cancer
- 643 Leukemia
- 767 Liver Cancer
- 4K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 217 Multiple Myeloma
- 7.1K Ovarian Cancer
- 35 Pancreatic Cancer
- 477 Peritoneal Cancer
- 5K Prostate Cancer
- 1.1K Rare and Other Cancers
- 521 Sarcoma
- 693 Skin Cancer
- 633 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.7K Uterine Cancer
- 6.2K Other Discussion Boards